{"id":233111,"date":"2025-01-13T18:54:19","date_gmt":"2025-01-13T18:54:19","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=233111"},"modified":"2025-01-13T18:54:19","modified_gmt":"2025-01-13T18:54:19","slug":"germanii-de-la-boehringer-amendati-de-consiliul-concurentei-cu-25-mil-euro-pentru-limitarea-accesului-pe-piata-a-unui-medicament-mai-ieftin","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=233111","title":{"rendered":"Germanii de la Boehringer, amenda\u0163i de Consiliul Concuren\u0163ei cu 25 mil. euro pentru limitarea accesului pe pia\u0163\u0103 a unui medicament mai ieftin"},"content":{"rendered":"<p>\nCompania farmaceutic\u0103 german\u0103&nbsp;Boehringer&nbsp;a fost amendat\u0103 de Consiliul Concuren\u0163ei cu peste 25 mil. euro pentru abuz de pozi\u0163ie dominant\u0103 pe pia\u0163a local\u0103 de medicamente, \u00een urma unei investiga\u0163ii a autorit\u0103\u0163ii de concuren\u0163\u0103 din 2021. Astfel, potrivit anchetei,&nbsp;Boehringer&nbsp;a limitat accesul pe pia\u0163a local\u0103 a unui medicament mai ieftin, direc\u0163ion\u00e2nd pacien\u0163ii spre o variant\u0103 de produs mai scump\u0103, tot din portofoliul propriu.<\/p>\n<p>\nAcest lucru s-a petrecut pe o perioad\u0103 de patru ani, \u00eentre 2017 \u015fi 2021, potrivit Concuren\u0163ei, iar tratamentul era destinate pacien\u0163ilor cu&nbsp;bronhopneumopatiei cronice obstructive (BPOC), o boal\u0103 de pl\u0103m\u00e2ni.<\/p>\n<p>\nPractic,&nbsp;Boehringer&nbsp;direc\u0163iona pacien\u0163ii c\u0103tre medicamentul inovativ&nbsp;Spiolto Respimat, care \u00een prezent cost\u0103 200 lei (potrivit site-ului Farmaciei Tei), limit\u00e2nd accesul medicamentului generic&nbsp;Spiriva, mai ieftin cu 100 de lei.<\/p>\n<p>\n\u201ePrin aceast\u0103 practic\u0103 de a \u00eencuraja prescrierea precoce a unui medicament mai complex \u015fi mai scump, compania a obligat unii pacien\u0163i s\u0103 pl\u0103teasc\u0103 mai mult pentru un medicament care nu le era indicat. \u00cen acela\u015fi timp, cu bugetul alocat decont\u0103rii noului produs, statul ar fi putut deconta medicamentele generice pentru mai mul\u0163i pacien\u0163i\u201d, a declarat Bogdan Chiri\u0163oiu, pre\u015fedintele Consiliului Concuren\u0163ei.<\/p>\n<p>\nConform Ghidului terapeutic \u00een vigoare \u00een acea perioad\u0103 \u015fi protocolului na\u0163ional, nu to\u0163i pacien\u0163ii afecta\u0163i de BPOC au ca prim\u0103 op\u0163iune de tratament un medicament mai complex (dubl\u0103 terapie), o parte dintre ace\u015ftia av\u00e2nd ca indica\u0163ie ini\u0163ial\u0103&nbsp;medicamentul Spiriva \u015fi implicit versiunile generice ale acestuia (monoterapia), se mai arat\u0103 \u00een comunicatul Concuren\u0163ei. Autoritatea mai arat\u0103 c\u0103&nbsp;Boehringer&nbsp;a&nbsp;derulat o strategie intensiv\u0103 de comunicare \u015fi promovare&nbsp;pentru a influen\u0163a&nbsp;decizia medicilor astfel \u00eenc\u00e2t ace\u015ftia s\u0103 prescrie generalizat medicamentul Spiolto Respimat.<\/p>\n<p>\nAmbele medicamente sunt decontate \u00een procent de 50% de Casa de Asigur\u0103ri de S\u0103n\u0103tate, diferen\u0163a fiind pl\u0103tit\u0103 de pacien\u0163i.<\/p>\n<p>\nBoehringer&nbsp;a avut \u00een 2023 afaceri de 544 mil. lei, potrivit datelor publice, \u00een cre\u015ftere cu 30% fa\u0163\u0103 de anul anterior. Compania a avut profit de 8,5 mil. lei \u015fi 70 de angaja\u0163i.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Compania farmaceutic\u0103 german\u0103&nbsp;Boehringer&nbsp;a fost amendat\u0103 de Consiliul Concuren\u0163ei cu peste 25 mil. euro pentru abuz de pozi\u0163ie dominant\u0103 pe pia\u0163a local\u0103 de medicamente, \u00een urma unei investiga\u0163ii a autorit\u0103\u0163ii de concuren\u0163\u0103 din 2021. Astfel, potrivit anchetei,&nbsp;Boehringer&nbsp;a limitat accesul pe pia\u0163a local\u0103 a unui medicament mai ieftin, direc\u0163ion\u00e2nd pacien\u0163ii spre o variant\u0103 de produs mai scump\u0103, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[9124,59448,8596,323],"class_list":["post-233111","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-amenda","tag-boehringer","tag-consiliul-concurentei","tag-medicamente"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/233111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=233111"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/233111\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=233111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=233111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=233111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}